AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02508662 — intervention group
Intervention type: OTHER
Intervention: Review of Screening Tests and Molecular Test Results
Description: Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
Study NCT03090568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-453
Description: BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
Study NCT04499963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theracurmin HP
Description: The intervention is based on the twice daily dosage of Theracurmin 90 mg capsules used in a trial of patients with mild cognitive impairment
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Serum
Description: FMTVDM Planar, SPECT, PET
Study NCT01604811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permixon® 160 mg
Description: Oral administration - 160 mg twice daily.
Study NCT01604811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosine Arrow LP
Description: Oral administration - 0.4 mg daily.
Study NCT01604811 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.
Study NCT03116867 — intervention group
Intervention type: OTHER
Intervention: sonosalpingography
Description: transvaginal ultrasound with saline infusion
Study NCT02626611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
Study NCT01604811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Tamsulosine Arrow LP
Description: Oral administration - daily.
Study NCT01880060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INCENT weight loss program
Description: Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; >20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
Study NCT02626611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
Study NCT02626611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Food Flour Buildup
Description: Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
Study NCT02626611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Food Flour Buildup
Description: Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
Study NCT02927626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yang Yin Fu Zheng therapy
Description: Yang Yin Fu Zheng is a Chinese herbal compound.
Study NCT02927626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Routine medical care
Description: Routine medical care
Study NCT02927626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine medical care
Description: Routine medical care
Study NCT01334047 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-006 vaccine
Description: Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
Study NCT03334097 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal education
Description: Education intervention will consist of a total of six sessions one week apart, with two hours of duration each one. The sessions that are exclusively oriented towards preparation for childbirth are session 1 and session 2. The content of each session is:~1. St. Birth: Start of childbirth, Symptoms and Signs, Delivery schedules, Phases of childbirth, Normal childbirth, Other circumstances (Obstetrical pathology / previous pathology, Induction of labor, Instrumental birth, Caesarean section).~2. nd:methods for relieving birth pain: Alternative Methods of Pain Relief, Pharmacological analgesia, Regional analgesia. Local and regional anesthesia, General anesthesia, breathing training and accompaniment during childbirth-~3. rd: Puerperium.~4. rd :Breastfeeding~5. rd : Newborn care~6. rd :Positive parenting.
Study NCT00111098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
Study NCT01880060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Livin My Weigh
Description: Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
Study NCT02352259 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
Study NCT02352259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cliniporator Vitae®
Description: Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
Study NCT02352259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin PHC 15 e. (United States Pharmacopeia - USP)
Description: Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
Study NCT02259322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care
Description: Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
Study NCT02259322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss Treatment
Description: Biweekly individual guided self-help sessions for 3 months
Study NCT02259322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Biweekly individual guided self-help sessions for 3 months
Study NCT02187055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib with methotrexate
Description: Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Study NCT02187055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib without methotrexate
Description: Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Study NCT02187055 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab with methotrexate
Description: Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
Study NCT03915457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry immersion Control Group
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water.
Study NCT01172145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
Study NCT01172145 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
Study NCT02009462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artefill dermal filler
Description: Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
Study NCT04487691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nebulized Platelet Lysate
Description: Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and platelet lysate (PL), maximizing the patients baseline platelet levels (\~2-4x baseline) will be produced in a clean room setting using the Regenexx, LLC proprietary lab protocols (PL-M) utilizing a double lysis technique. From that sample, a high growth factor lysate will be created using a double lysis technique, and a sample will be retained to quantify the protein profile of the PL via ELISA quantitative analysis. The PL will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the platelet lysate following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
Study NCT04487691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sterile Saline
Description: Approximately 520 cc of autologous venous blood (within AABB guideline limits) will be drawn and donated for research purposes to keep patient blinded to group allocation. Sterile normal saline to mimic the appearance of the platelet lysate will be aliquoted into 56 (n=28x2) 2-ml ampules using sterile technique which will then be frozen at -20°C. The patient will unfreeze each ampule and place it into a handheld ultrasonic nebulizer and inhale the sterile saline following the nebulizer manufacture's protocol until the treatment is completed. The treatment will be applied once a day for 8-weeks.
Study NCT02615028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Closed eyes double-leg stance
Description: Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
Study NCT02284750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention
Study NCT02284750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Study NCT03545451 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videogames
Description: Videogames
Study NCT01783561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
Study NCT01783561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine
Description: Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
Study NCT01852747 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multilevel Spinal fusion with Actifuse ABX®
Description: Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
Study NCT03266263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatic computer-led feedback
Description: automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume
Study NCT03266263 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: instructor-led feedback
Description: feedback for CPR quality by instructors
Study NCT01111461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
Study NCT01352091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex+AI
Description: Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
Study NCT01352091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAM
Description: Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
Study NCT01377779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxiplex/AP gel
Description: Intrauterine application of Intercoat following hysteroscopy
Study NCT01377779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: No intrauterine application of Intercoat following hysteroscopy
Study NCT04203147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy (Control)
Description: Description: 8-weekly sessions of in-home, supportive therapy and monthly booster sessions from months 3-12 via telephone.
Study NCT04203147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home DM-BAT
Description: Description: 8-weekly sessions of in-home, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) and monthly booster sessions from months 3-12 via telephone.
Study NCT01289691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Lung Ventilation
Description: Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
Study NCT01289691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One Lung Ventilation
Description: Patients in this group will be ventilated with only oxygen during one lung ventilation.
Study NCT01689311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study NCT01689311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergonovine
Description: Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study NCT01689311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostaglandin F2alpha
Description: Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study NCT01689311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
Study NCT03706794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support Tool
Description: Tailored education provided via a smartphone application.
Study NCT03706794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Headache Education
Description: Non-tailored education provided via a smartphone application.
Study NCT03378492 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Epidural
Description: Sterile ultrasound gel will be applied to the patient's back and the sterile device will be used to image the lumbar vertebrae in the area of the palpation-derived location. When the device is placed above the vertebral interspace, the 3D image mode will identify the spine midline and the depth from the skin to the epidural space. A single 3D ultrasound video loop of the vertebral interspace will be saved to confirm correct landmark identification. After identification of the vertebral interspace, the skin will be marked with a marking utensil or physical indentation at the point of needle entry indicated by the device. The epidural needle will then be placed in the same fashion as in the standard procedure group. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance.
Study NCT03378492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Epidural
Description: The point of needle entry will be located using the landmarks technique. The specific level of epidural placement will be determined on a per-patient basis at the anesthesiologist's discretion. The spine midline will also be palpated to determine the approximate location of an interlaminar space. The needle will then be inserted at the appropriate location determined by the landmarks technique, and successful epidural placement will be confirmed by observation of loss of resistance and follow-up confirmation of analgesia. The depth of the epidural needle placement will be measured and recorded following observation of loss of resistance. The epidural catheter will be inserted and the procedure will continue according to the standard of care.
Study NCT01986491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 39393406 30 mg solid X
Description: Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
Study NCT00722371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
Study NCT00722371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to sitagliptin
Description: Matching placebo to sitagliptin orally once daily for 54 weeks.
Study NCT00722371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to pioglitazone
Description: Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
Study NCT00722371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
Study NCT03915457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thigh cuffs intervention
Description: Subjects are immersed up to the neck for 5 days in a specially designed bath filled with tap water. During the 5 days of dry immersion, the subjects will wear the thigh cuffs daily for 10 hours during the day (8 am to 6 pm). Thigh cuffs are strips of fabric with inserts of elastic fabric. Different sizes exist to adapt to different thighs. Each cuff has five tightening positions (from 1 to 5) and they will be tightened at the upper third of the thighs to create an occlusion pressure of about 30 mmHg.
Study NCT04588272 — intervention group
Intervention type: DEVICE
Intervention: DualGuard
Description: DualGuard device (FlexiCare) which incorporate an endoscopy bite block with oxygen delivery and CO2 monitoring from both the mouth and nose simultaneously.